Elafibranor fails interim analysis of RESOLVE-IT Phase III trial of non-alcoholic steatohepatitis (NASH)

The RESOLVE-IT trial of this PPAR agonist (n=1,070) failed to hit the predefined primary endpoint of NASH resolution without fibrosis (response rate 19.2% vs 14.7% with placebo) and the key secondary endpoint, improvement in fibrosis (24% vs 22.4%).


Biospace Inc.